Initial CT Perfusion-Guided Strategy for Suspected NSTEMI

NCT ID: NCT06689267

Last Updated: 2025-09-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-01

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Non-ST elevation myocardial infarction (NSTEMI) is a relatively complex type of myocardial infarction, characterized by chest pain symptoms and elevated troponin levels. However, some patients initially diagnosed with suspected NSTEMI are found not to have severe stenosis upon coronary angiography. Recent studies have shown that initial imaging examinations (including CTA and CMR) in suspected NSTEMI patients can help reduce the need for coronary angiography. The diagnostic value of CT perfusion (CTP) has been established in patients with stable coronary artery disease, but relevant studies have not yet been conducted in suspected NSTEMI patients. This study aims to explore the diagnostic and therapeutic value of an initial CTP strategy for suspected NSTEMI patients. Additionally, we will conduct a cardiovascular health questionnaire to investigate the impact and prognostic value of factors such as adverse lifestyle and inflammation levels in these patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute myocardial infarction (AMI) is caused by acute and persistent ischemia and hypoxia of the coronary arteries, leading to myocardial necrosis. Clinically, it often presents as severe and prolonged retrosternal pain, accompanied by elevated serum myocardial enzyme levels and progressive changes in the electrocardiogram (ECG). Complications may include arrhythmias, shock, or heart failure, which can be life-threatening.

Non-ST elevation myocardial infarction (NSTEMI) is a more complex type of AMI. It presents with chest pain and elevated troponin levels, but without clear ischemic changes on the ECG, making clinical diagnosis challenging. Additionally, NSTEMI patients are highly heterogeneous, influenced by factors like lifestyle and inflammation. Current clinical guidelines recommend coronary angiography for these patients. However, previous studies have shown that approximately one-third of suspected NSTEMI patients do not exhibit significant coronary stenosis on angiography. Minimizing unnecessary invasive coronary angiography for such patients has become a pressing issue.

Recent clinical studies have explored the value of initial imaging tests in guiding treatment strategies for NSTEMI patients. The CARMENTA study found that performing CTA or MRI as the first-line test in suspected NSTEMI patients could reduce the need for subsequent invasive coronary angiography by 13% and 34%, respectively, and improve the positive detection rate on later angiography. The OxAMI study also showed that in patients with suspected NSTEMI who underwent MRI, only 67% had myocardial infarction, and even among those who subsequently underwent angiography and were found to have severe stenosis, CMR indicated infarction in only 84%. These findings suggest that while CTA can help rule out some myocardial infarction cases, its diagnostic value in suspected NSTEMI remains limited.

With advances in imaging technology, CT myocardial perfusion (CTP) has shown potential in more accurately identifying ischemic myocardium in coronary artery disease patients, thereby enhancing the diagnostic power of CTA. However, the diagnostic value of CTP for suspected NSTEMI patients remains unclear. Furthermore, technology now allows for simultaneous CTA and CTP testing without significantly increasing radiation exposure. This combined approach offers promise for more accurate diagnosis in suspected NSTEMI patients without a marked increase in radiation dose.

Therefore, this study aims to investigate the diagnostic and therapeutic value of an initial CTP strategy in suspected NSTEMI patients. Additionally, we will conduct a cardiovascular health questionnaire survey to explore the impact and prognostic value of adverse lifestyle factors and inflammation levels in these patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-ST Elevation Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Initial CT perfusion

Patients enrolled in the Initial CT perfusion group will first undergo CTA and CTP examinations. Based on the results of these tests, the treatment team will then decide whether to proceed with conservative medical therapy or perform coronary angiography.

Group Type EXPERIMENTAL

computed tomography myocardial perfusion

Intervention Type DIAGNOSTIC_TEST

The diagnostic value of CT perfusion (CTP) has been established in patients with stable coronary artery disease, but relevant studies have not yet been conducted in suspected NSTEMI patients. This study aims to explore the diagnostic and therapeutic value of an initial CTP strategy for suspected NSTEMI patients.

Invasive Coronary Angiography

Patients enrolled in the Invasive Coronary Angiography group will directly undergo coronary angiography. If necessary, intracoronary imaging (including IVUS and OCT) will be performed. Based on the results of these tests, the treatment team will then decide whether to proceed with conservative medical therapy or interventional treatment (including stent implantation or balloon angioplasty).

Group Type ACTIVE_COMPARATOR

Invasive Coronary Angiography

Intervention Type PROCEDURE

Patients enrolled in the Invasive Coronary Angiography group will directly undergo coronary angiography. If necessary, intracoronary imaging (including IVUS and OCT) will be performed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

computed tomography myocardial perfusion

The diagnostic value of CT perfusion (CTP) has been established in patients with stable coronary artery disease, but relevant studies have not yet been conducted in suspected NSTEMI patients. This study aims to explore the diagnostic and therapeutic value of an initial CTP strategy for suspected NSTEMI patients.

Intervention Type DIAGNOSTIC_TEST

Invasive Coronary Angiography

Patients enrolled in the Invasive Coronary Angiography group will directly undergo coronary angiography. If necessary, intracoronary imaging (including IVUS and OCT) will be performed.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with stable chest tightness or chest pain, aged ≥18 years
2. No ST elevation or dynamic ST-T changes on the ECG
3. Elevated TNT (greater than 14 ng/L three hours after symptom onset)

Exclusion Criteria

1. Persistent chest pain or ECG indicating dynamic ST-T changes,
2. Hemodynamic instability
3. Known history of coronary artery disease
4. Contraindications for CT perfusion or coronary angiography
5. Coexisting conditions such as pregnancy, cancer, severe valvular heart disease, or liver/kidney dysfunction
6. Other diseases with a life expectancy of less than one year
7. Inability to sign informed consent or, in the researcher's judgment, poor compliance, making it unlikely the patient can complete the study as required.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shanghai Zhongshan Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Junbo Ge

Director of the Department of Cardiology, Professor, Academician of the Chinese Academy of Sciences.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Junbo Ge, PhD

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, China

Site Status NOT_YET_RECRUITING

Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Wei Gao, PhD

Role: CONTACT

86-13661959824

Yan Xia, PhD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

gao wei

Role: primary

Wei Gao, PHD

Role: primary

86+13661959824

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZS-SMART

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.